Compare MCI & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCI | PACB |
|---|---|---|
| Founded | 1971 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.7M | 419.8M |
| IPO Year | N/A | 2010 |
| Metric | MCI | PACB |
|---|---|---|
| Price | $17.58 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.10 |
| AVG Volume (30 Days) | 19.2K | ★ 4.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | N/A | $12.41 |
| P/E Ratio | $10.17 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $18.00 | $0.85 |
| 52 Week High | $23.79 | $2.73 |
| Indicator | MCI | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 20.01 | 34.36 |
| Support Level | N/A | $1.19 |
| Resistance Level | $21.19 | $1.37 |
| Average True Range (ATR) | 0.52 | 0.09 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 4.80 | 6.82 |
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.